tiprankstipranks
PTC Therapeutics (PTCT)
NASDAQ:PTCT
US Market
PTCT
PTC Therapeutics
RESEARCH TOOLSreports
Want to see PTCT full AI Analyst Report?

PTC Therapeutics (PTCT) Stock Forecast & Price Target

409 Followers
See the Price Targets and Ratings of:

PTCT Analyst Ratings

Strong Buy
13Ratings
Strong Buy
10 Buy
3 Hold
0 Sell
Based on 13 analysts giving stock ratings to
PTC
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PTCT Stock 12 Month Forecast

Average Price Target

$93.10
▲(28.54% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $93.10 with a high forecast of $124.00 and a low forecast of $75.00. The average price target represents a 28.54% change from the last price of $72.43.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"47":"$47","86":"$86","125":"$125","66.5":"$66.5","105.5":"$105.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$124.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$93.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[47,66.5,86,105.5,125],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.15,69.67692307692309,74.20384615384616,78.73076923076924,83.25769230769231,87.78461538461539,92.31153846153848,96.83846153846154,101.36538461538461,105.8923076923077,110.41923076923078,114.94615384615385,119.47307692307693,{"y":124,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.15,67.30000000000001,69.45,71.60000000000001,73.75,75.9,78.05,80.2,82.35,84.5,86.64999999999999,88.8,90.94999999999999,{"y":93.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.15,65.90769230769232,66.66538461538462,67.42307692307693,68.18076923076923,68.93846153846154,69.69615384615385,70.45384615384616,71.21153846153847,71.96923076923078,72.72692307692307,73.48461538461538,74.24230769230769,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":49.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.83,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.43,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.31,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.37,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.75,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$124.00Average Price Target$93.10Lowest Price Target$75.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on PTCT
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (NASDAQ: KALV), PTC Therapeutics (NASDAQ: PTCT) and Veru (NASDAQ: VERU)
J.P. Morgan Analyst forecast on PTCT
Brian Cheng
J.P. Morgan
J.P. Morgan
$80→$89
Buy
22.88%
Upside
Reiterated
05/11/26
PTC Therapeutics price target raised to $89 from $80 at JPMorganPTC Therapeutics price target raised to $89 from $80 at JPMorgan
Barclays Analyst forecast on PTCT
Eliana Merle
Barclays
Barclays
$120
Buy
65.68%
Upside
Reiterated
05/11/26
Barclays Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
TD Cowen Analyst forecast on PTCT
Joseph Thome
TD Cowen
TD Cowen
$75→$90
Buy
24.26%
Upside
Upgraded
05/08/26
Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), Palvella Therapeutics (PVLA)
Raymond James Analyst forecast on PTCT
Tiago Fauth
Raymond James
Raymond James
$86→$95
Buy
31.16%
Upside
Reiterated
05/08/26
PTC Therapeutics (PTCT) Gets a Buy from Raymond James
Morgan Stanley Analyst forecast on PTCT
Judah Frommer
Morgan Stanley
Morgan Stanley
$92→$94
Buy
29.78%
Upside
Reiterated
05/08/26
Morgan Stanley Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
Citi Analyst forecast on PTCT
Geoff Meacham
Citi
Citi
$75
Hold
3.55%
Upside
Reiterated
05/07/26
PTC Therapeutics (PTCT) Gets a Hold from Citi
RBC Capital Analyst forecast on PTCT
Brian Abrahams
RBC Capital
RBC Capital
$81→$82
Hold
13.21%
Upside
Reiterated
05/07/26
RBC Capital Sticks to Their Hold Rating for PTC Therapeutics (PTCT)
Cantor Fitzgerald Analyst forecast on PTCT
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$124
Buy
71.20%
Upside
Reiterated
04/28/26
Cantor Fitzgerald Keeps Their Buy Rating on PTC Therapeutics (PTCT)
Wells Fargo Analyst forecast on PTCT
Benjamin Burnett
Wells Fargo
Wells Fargo
$86
Buy
18.74%
Upside
Reiterated
04/13/26
PTC Therapeutics (PTCT) Receives a Buy from Raymond James
Jefferies Analyst forecast on PTCT
Faisal Khurshid
Jefferies
Jefferies
$91→$76
Hold
4.93%
Upside
Downgraded
03/30/26
PTC Therapeutics assumed at Hold from Buy at JefferiesPTC Therapeutics assumed at Hold from Buy at Jefferies
Truist Financial Analyst forecast on PTCT
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
02/27/26
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Neurogene (NGNE)
William Blair Analyst forecast on PTCT
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
02/20/26
PTC Therapeutics: Sephience Uptake, Advancing Pipeline, and Strengthening Financials Support Buy Rating
Goldman Sachs Analyst forecast on PTCT
Paul Choi
Goldman Sachs
Goldman Sachs
$50→$55
Sell
-24.06%
Downside
Reiterated
12/03/25
PTC Therapeutics (PTCT) Gets a Sell from Goldman Sachs
Leerink Partners Analyst forecast on PTCT
Joseph Schwartz
Leerink Partners
Leerink Partners
$54
Hold
-25.45%
Downside
Reiterated
10/16/25
Wall Street Analysts Are Neutral on Top Healthcare Picks
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on PTCT
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (NASDAQ: KALV), PTC Therapeutics (NASDAQ: PTCT) and Veru (NASDAQ: VERU)
J.P. Morgan Analyst forecast on PTCT
Brian Cheng
J.P. Morgan
J.P. Morgan
$80→$89
Buy
22.88%
Upside
Reiterated
05/11/26
PTC Therapeutics price target raised to $89 from $80 at JPMorganPTC Therapeutics price target raised to $89 from $80 at JPMorgan
Barclays Analyst forecast on PTCT
Eliana Merle
Barclays
Barclays
$120
Buy
65.68%
Upside
Reiterated
05/11/26
Barclays Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
TD Cowen Analyst forecast on PTCT
Joseph Thome
TD Cowen
TD Cowen
$75→$90
Buy
24.26%
Upside
Upgraded
05/08/26
Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), Palvella Therapeutics (PVLA)
Raymond James Analyst forecast on PTCT
Tiago Fauth
Raymond James
Raymond James
$86→$95
Buy
31.16%
Upside
Reiterated
05/08/26
PTC Therapeutics (PTCT) Gets a Buy from Raymond James
Morgan Stanley Analyst forecast on PTCT
Judah Frommer
Morgan Stanley
Morgan Stanley
$92→$94
Buy
29.78%
Upside
Reiterated
05/08/26
Morgan Stanley Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
Citi Analyst forecast on PTCT
Geoff Meacham
Citi
Citi
$75
Hold
3.55%
Upside
Reiterated
05/07/26
PTC Therapeutics (PTCT) Gets a Hold from Citi
RBC Capital Analyst forecast on PTCT
Brian Abrahams
RBC Capital
RBC Capital
$81→$82
Hold
13.21%
Upside
Reiterated
05/07/26
RBC Capital Sticks to Their Hold Rating for PTC Therapeutics (PTCT)
Cantor Fitzgerald Analyst forecast on PTCT
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$124
Buy
71.20%
Upside
Reiterated
04/28/26
Cantor Fitzgerald Keeps Their Buy Rating on PTC Therapeutics (PTCT)
Wells Fargo Analyst forecast on PTCT
Benjamin Burnett
Wells Fargo
Wells Fargo
$86
Buy
18.74%
Upside
Reiterated
04/13/26
PTC Therapeutics (PTCT) Receives a Buy from Raymond James
Jefferies Analyst forecast on PTCT
Faisal Khurshid
Jefferies
Jefferies
$91→$76
Hold
4.93%
Upside
Downgraded
03/30/26
PTC Therapeutics assumed at Hold from Buy at JefferiesPTC Therapeutics assumed at Hold from Buy at Jefferies
Truist Financial Analyst forecast on PTCT
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
02/27/26
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Neurogene (NGNE)
William Blair Analyst forecast on PTCT
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
02/20/26
PTC Therapeutics: Sephience Uptake, Advancing Pipeline, and Strengthening Financials Support Buy Rating
Goldman Sachs Analyst forecast on PTCT
Paul Choi
Goldman Sachs
Goldman Sachs
$50→$55
Sell
-24.06%
Downside
Reiterated
12/03/25
PTC Therapeutics (PTCT) Gets a Sell from Goldman Sachs
Leerink Partners Analyst forecast on PTCT
Joseph Schwartz
Leerink Partners
Leerink Partners
$54
Hold
-25.45%
Downside
Reiterated
10/16/25
Wall Street Analysts Are Neutral on Top Healthcare Picks
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering PTC Therapeutics

3 Months
xxx
Success Rate
13/17 ratings generated profit
76%
Average Return
+15.82%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +15.82% per trade.
1 Year
Joel BeattyRobert W. Baird
Success Rate
16/17 ratings generated profit
94%
Average Return
+52.56%
Copying Joel Beatty's trades and holding each position for 1 Year would result in 94.12% of your transactions generating a profit, with an average return of +52.56% per trade.
2 Years
xxx
Success Rate
16/17 ratings generated profit
94%
Average Return
+82.80%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +82.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PTCT Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
3
3
3
6
5
Buy
18
18
13
11
8
Hold
9
10
10
7
5
Sell
2
1
0
0
0
Strong Sell
0
0
0
0
0
total
32
32
26
24
18
In the current month, PTCT has received 13 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. PTCT average Analyst price target in the past 3 months is 93.10.
Each month's total comprises the sum of three months' worth of ratings.

PTCT Financial Forecast

PTCT Earnings Forecast

Next quarter’s earnings estimate for PTCT is $0.27 with a range of -$0.41 to $1.14. The previous quarter’s EPS was -$0.03. PTCT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PTCT has Performed in-line its overall industry.
Next quarter’s earnings estimate for PTCT is $0.27 with a range of -$0.41 to $1.14. The previous quarter’s EPS was -$0.03. PTCT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PTCT has Performed in-line its overall industry.

PTCT Sales Forecast

Next quarter’s sales forecast for PTCT is $289.66M with a range of $253.01M to $317.18M. The previous quarter’s sales results were $272.55M. PTCT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PTCT has Performed in-line its overall industry.
Next quarter’s sales forecast for PTCT is $289.66M with a range of $253.01M to $317.18M. The previous quarter’s sales results were $272.55M. PTCT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PTCT has Performed in-line its overall industry.

PTCT Stock Forecast FAQ

What is PTCT’s average 12-month price target, according to analysts?
Based on analyst ratings, PTC Therapeutics’s 12-month average price target is 93.10.
    What is PTCT’s upside potential, based on the analysts’ average price target?
    PTC Therapeutics has 28.54% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PTCT a Buy, Sell or Hold?
          PTC Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 3 hold ratings and 0 sell ratings.
            What is PTC Therapeutics’s price target?
            The average price target for PTC Therapeutics is 93.10. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $124.00 ,the lowest forecast is $75.00. The average price target represents 28.54% Increase from the current price of $72.43.
              What do analysts say about PTC Therapeutics?
              PTC Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of PTCT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.